No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
383 |
4. Check minimum number of eventsNone |
383 |
5. Include endpointsNone |
383 |
6. Filter based on genotype QC (FinnGen only) |
383 |
Control definitions (FinnGen only)
- Control exclude
- G6_DEMYEL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G35-G37
- Name in latin
- Alia demyelinatio disseminata acuta
Similar endpoints
↥List of similar endpoints to
Other acute disseminated demyelination
based on the number of shared cases.
Similar with more cases:
- Demyelinating diseases of the central nervous system
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2214 | 1475 | 720 |
| Only index persons | 2052 | 1408 | 644 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.02 |
| Only index persons | 0.04 | 0.05 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 38.77 | 38.00 | 40.00 |
| Only index persons | 37.80 | 37.69 | 38.05 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 383 | 288 | 95 |
| Unadjusted period prevalence (%) | 0.08 | 0.10 | 0.04 |
| Median age at first event (years) | 37.80 | 36.62 | 41.38 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 341
- Matched controls
- 3410
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
+∞
286.5
233
*
G35
ICD-10 Finland
Multiple sclerosis
7425.5
278.1
229
*
109
Kela drug reimbursment
Multiple sclerosis
+∞
203.1
174
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
+∞
188.6
163
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
180.8
157
*
L03AB07
ATC
interferon beta-1a; parenteral
+∞
109.4
99
*
H46
ICD-10 Finland
Optic neuritis
486.8
107.8
102
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
+∞
98.9
90
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
17.7
92.8
160
162
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
91.9
84
*
L03AX13
ATC
glatiramer acetate; parenteral
+∞
88.5
81
*
TAB00
NOMESCO Finland
Lumbar puncture
22.0
73.9
112
74
N86
ICPC
Multiple sclerosis
+∞
60.2
56
*
164
Kela drug reimbursment
Fingolimod
+∞
56.9
53
*
353
Kela drug reimbursment
Cladribine and fingolimod
+∞
50.3
47
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
10.0
46.1
100
136
L04AX07
ATC
dimethyl fumarate; oral
+∞
45.9
43
*
N07XX09
ATC
[U] dimethyl fumarate; oral
+∞
45.9
43
*
L04AA31
ATC
teriflunomide; oral
+∞
43.7
41
*
L04AA27
ATC
fingolimod; oral
+∞
43.7
41
*
L03AB08
ATC
interferon beta-1b; parenteral
+∞
42.6
40
*
N04BB01
ATC
amantadine; oral
49.3
39.3
47
11
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
29.8
38.0
51
20
XA800
NOMESCO Finland
Neuropsychological investigation
13.0
32.0
58
53
XCK00
NOMESCO Finland
Perimetry
10.2
31.5
65
77
ZX120
NOMESCO Finland
Intravenous
7.3
30.6
79
135
2AB04
NOMESCO Finland
NA
169.9
30.2
31
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.1
29.5
108
285
R20.2
ICD-10 Finland
Paraesthesia of skin
7.2
28.6
74
126
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
28.3
28.2
38
15
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
23.0
27.2
39
19
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.5
27.0
76
145
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.9
24.2
45
43
M03BX01
ATC
baclofen; systemic
22.0
23.5
34
17
G36.8
ICD-10 Finland
Other specified acute disseminated demyelination
+∞
23.2
22
*
XKC03
NOMESCO Finland
Water cystometry
20.8
23.1
34
18
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
8.8
23.1
51
67
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
7.5
22.5
55
85
N03AX12
ATC
gabapentin; oral
4.1
20.5
89
268
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
20.0
19
*
H53.2
ICD-10 Finland
Diplopia
12.4
19.5
35
31
XKD06
NOMESCO Finland
Physiologic investigation of micturition
13.9
19.4
33
26
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
14.8
18.1
30
22
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
30.7
17.7
23
8
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
20.0
17.6
26
14
XCD10
NOMESCO Finland
Electrophysiological examination of eye
16.2
17.0
27
18
N06BA07
ATC
modafinil; oral
94.8
16.7
18
*
4AA23
NOMESCO Finland
NA
+∞
15.7
15
*
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
15.7
15
*
UKC02
NOMESCO Finland
Cystoscopy
4.0
14.9
63
181
H02AB04
ATC
methylprednisolone; systemic
3.5
14.9
79
272
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
11.2
14.5
27
26
G04BD09
ATC
trospium; oral
13.7
13.1
22
17
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
72.6
12.7
14
*
XKD00
NOMESCO Finland
Uroflowmetry
4.2
12.6
49
130
XKD03
NOMESCO Finland
Urethral pressure profilometry
12.3
12.5
22
19
N05CF01
ATC
zopiclone; oral
2.5
12.3
116
575
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
27.9
12.2
16
6
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
31.3
11.7
15
5
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
23.9
11.7
16
7
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
11.5
11
*
G04BD08
ATC
solifenacin; oral
5.8
11.0
31
58
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
10.6
138
793
G36.1
ICD-10 Finland
Acute and subacute haemorrhagic leukoencephalitis [Hurst]
+∞
10.5
10
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.2
10.2
39
102
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
9.6
10.2
20
22
G04BD12
ATC
mirabegron; oral
3.9
9.5
39
109
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
9.4
9
*
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
+∞
9.4
9
*
R1250
NOMESCO Finland
Evaluation of functional capability
9.9
9.4
18
19
N06AX21
ATC
duloxetine; oral
2.9
9.2
57
219
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
8.9
90
452
L04AX01
ATC
azathioprine; systemic
4.7
8.8
29
66
N03AE01
ATC
clonazepam; systemic
3.7
8.8
38
112
WW400
NOMESCO Finland
Plasmaferesis
51.3
8.7
10
*
TKC22
NOMESCO Finland
Catheterisation instruction
10.4
8.6
16
16
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
92.2
8.5
9
*
L04AA40
ATC
cladribine; oral
+∞
8.4
8
*
A28
ICPC
Limited function/disability NOS
3.6
8.3
37
112
N99
ICPC
Neurological disease other
15.0
8.3
13
9
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
22.7
8.1
11
5
H57.1
ICD-10 Finland
Ocular pain
4.9
7.7
24
52
J01EA01
ATC
trimethoprim; systemic
2.1
7.6
95
524
N03AX16
ATC
pregabalin; oral
2.2
7.6
91
491
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.5
7.5
34
104
R35
ICD-10 Finland
Polyuria
4.2
7.4
27
69
H53.4
ICD-10 Finland
Visual field defects
9.7
7.4
14
15
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
16.2
7.3
11
7
XCK10
NOMESCO Finland
Photography of fundus of eye
3.3
7.2
35
114
A02BC02
ATC
pantoprazole; systemic
1.9
7.1
211
1589
N29
ICPC
Neurological sympt/complt other
10.3
7.1
13
13
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.2
7.1
36
121
H53.1
ICD-10 Finland
Subjective visual disturbances
3.8
7.0
28
78
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
6.9
92
515
XCW99
NOMESCO Finland
Other investigative procedure of eye
2.8
6.9
44
172
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
5.1
6.8
20
41
L28
ICPC
Limited function/disability (L)
2.7
6.7
44
175
G04BD11
ATC
fesoterodine; oral
6.7
6.7
16
25
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
5.7
6.7
18
33
SPAT1216
SPAT
Assessment of functional ability
2.7
6.7
45
179
N04BC05
ATC
pramipexole; oral
4.0
6.4
24
63
AA1AD
NOMESCO Finland
CT of head and brain
2.2
6.4
70
359
N28
ICPC
Limited function/disability (N)
8.4
6.4
13
16
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
8.4
6.4
13
16
R4150
NOMESCO Finland
Neuropsychological rehabilitation
9.5
6.3
12
13
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.2
6.3
31
102
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
6.3
6
*
CS494
NOMESCO Finland
Other visual field testing
6.9
6.1
14
21
G04BD07
ATC
tolterodine; oral
4.7
6.1
19
42
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
81
46
22.06
102.86
1.2
1.1
—
—
—
0
0
58
23
29.54
84.53
1.2
1.0
—
—
—
0
0
41
18
25.39
57.06
4.8
2.7
14.8
7.0
%
—
24
9
50
38
14.98
53.81
1.1
1.1
—
—
—
0
0
48
40
13.58
48.85
1.1
1.1
—
—
—
0
0
45
35
14.44
47.66
1.1
1.1
—
—
—
0
0
39
25
17.26
45.78
1.1
1.1
1.0
1.1
u/l
0.36
12
15
59
80
8.54
42.36
1.3
1.2
8.5
7.6
e6/l
0.07
51
64
59
80
8.54
42.36
1.4
1.3
172.5
180.3
e6/l
0.02
51
67
58
79
8.47
41.46
1.3
1.2
3.6
3.6
mmol/l
0.03
52
73
286
1523
4.47
38.51
15.3
5.8
27.5
29.3
%
1.92
279
1431
283
1506
4.37
37.89
15.2
5.6
58.1
56.7
%
1.18
278
1420
31
19
17.66
37.03
5.7
2.7
—
—
—
0
0
59
97
7.01
35.55
1.7
1.6
44.1
0.0
iu/ml
—
8
16
34
29
12.77
33.85
4.5
1.7
902.4
694.8
e6/l
—
17
8
26
15
18.52
31.85
1.2
1.1
1608.1
1756.5
miu/ml
0.17
26
15
295
1796
3.80
28.35
17.4
9.1
3.7
4.0
e9/l
1.88
281
1580
233
1267
3.14
26.27
2.8
2.2
91.3
74.3
nmol/l
10.56
223
1177
79
248
3.75
21.81
1.4
1.2
—
22.7
—
0
14
22
24
9.66
18.37
1.1
1.3
1.7
1.8
mmol/l
0.28
22
24
145
728
2.60
17.15
5.5
2.4
0.1
0.4
e6/l
1.87
117
534
25
37
7.16
16.33
1.1
1.1
—
—
—
0
0
88
356
2.91
15.72
2.0
2.0
28.3
29.6
s
1.67
83
350
183
1103
2.26
13.64
7.6
4.2
37.0
36.8
g/l
0.25
176
1039
18
8
23.52
13.01
3.8
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
15
16
9.72
12.62
1.3
1.3
—
—
—
0
0
18
26
7.22
11.96
1.4
1.3
—
—
—
0
0
89
420
2.46
11.42
4.7
2.2
0.5
1.0
e6/l
1.66
55
226
49
175
3.06
10.74
2.8
1.6
—
—
—
0
0
217
1519
1.99
9.78
8.0
4.2
0.0
0.0
estimate
0.50
44
293
216
1514
1.98
9.65
6.3
3.0
0.0
0.0
estimate
0.00
41
290
80
390
2.33
9.41
5.1
2.3
5.9
3.7
e6/l
0.36
48
198
216
1540
1.92
8.90
6.4
3.1
0.0
0.0
estimate
0.00
43
283
10
10
10.24
8.68
1.0
1.6
—
—
—
0
0
224
1632
1.90
8.47
5.6
4.0
6.5
6.4
mmol/l
0.12
210
1491
12
16
7.71
8.46
1.3
1.1
—
—
—
0
0
210
1504
1.88
8.33
8.0
5.6
10.2
10.1
umol/l
0.06
199
1428
11
14
8.06
8.03
1.2
1.2
—
—
—
0
0
12
8
15.43
7.76
1.0
1.1
—
—
—
0
0
12
8
15.43
7.76
1.0
1.3
—
—
—
0
0
287
2326
1.93
7.19
10.3
6.9
77.4
74.1
u/l
0.59
277
2194
32
121
2.79
6.33
1.4
1.3
—
—
—
0
0
10
8
12.79
6.11
1.0
1.5
—
—
—
0
0
10
9
11.37
5.82
1.0
1.3
—
—
—
0
0
87
529
1.83
5.43
1.7
1.6
113924500.1
26395284.2
pmol/l
0.35
79
466
280
2337
1.74
5.36
4.4
3.8
9.5
9.4
mm/h
0.02
269
2202
172
1274
1.64
5.21
8.3
6.0
1.2
1.2
mmol/l
0.05
142
1087
67
382
1.91
5.09
1.6
1.6
1189.2
1241.6
nmol/l
0.19
56
297
9
9
10.20
5.05
1.0
1.2
—
—
—
0
0
281
2370
1.70
4.93
6.1
2.8
48.3
39.3
u/l
1.02
273
2279
30
126
2.50
4.86
2.1
2.2
—
—
—
0
0
67
388
1.88
4.85
1.9
1.8
—
—
—
0
0
74
458
1.76
4.30
3.2
3.1
186.8
187.3
ng/l
0.00
31
278
34
164
2.18
4.06
1.2
1.3
146.5
250.0
miu/ml
1.57
11
87
7
7
10.16
4.02
3.1
3.3
—
—
—
0
0
10
24
4.25
3.91
1.1
1.5
—
—
—
0
0
143
1071
1.53
3.84
6.8
3.0
27.0
29.9
u/l
1.24
137
1018
6
5
12.16
3.77
1.0
1.0
—
—
—
0
0
43
234
1.94
3.74
2.5
2.2
356.8
3958.1
u/l
—
9
100
18
68
2.73
3.61
1.4
2.7
10.5
10.5
g/l
0.04
12
62
84
564
1.63
3.59
1.6
1.4
22.3
21.4
nmol/l
0.27
75
494
8
13
6.26
3.52
1.0
1.0
—
—
—
0
0
156
1209
1.49
3.49
7.3
3.1
—
—
—
0
0
16
58
2.84
3.46
3.8
3.7
3.6
4.4
e9/l
0.95
16
58
18
70
2.65
3.43
1.4
2.7
3.1
3.1
g/l
0.05
12
57
10
27
3.78
3.37
1.0
1.3
—
—
—
0
0
351
3254
1.94
3.29
17.8
10.8
18.3
19.5
mg/l
0.26
272
2503
94
662
1.56
3.27
7.2
3.3
1.0
1.0
kg/l
0.64
12
79
16
60
2.74
3.27
3.8
3.9
59.1
56.6
%
0.34
16
60
51
308
1.76
3.22
3.5
3.6
31.8
31.9
%
0.03
44
215
44
255
1.82
3.18
2.0
1.6
—
—
—
0
0
127
961
1.48
3.14
3.4
3.1
25.7
29.0
ng/l
0.12
71
515
146
1137
1.46
3.11
7.4
5.2
1.2
1.2
mmol/l
0.46
135
1051
22
100
2.27
3.06
1.5
1.7
—
—
—
0
0
109
805
1.49
3.02
9.1
3.3
0.0
0.0
estimate
0.50
43
290
18
75
2.47
3.01
1.4
2.6
3.3
3.8
g/l
0.83
12
56
18
75
2.47
3.01
1.4
2.6
7.3
7.6
g/l
0.15
12
60
18
75
2.47
3.01
1.4
2.6
—
—
—
0
0
5
5
10.11
2.98
1.0
1.0
—
—
—
0
0
5
5
10.11
2.98
1.0
1.0
—
—
—
0
0
342
3166
1.75
2.93
17.6
11.1
3.9
3.9
mmol/l
0.12
336
3079
22
104
2.18
2.80
1.3
1.1
—
—
—
0
0
293
3179
0.67
2.74
3.9
3.7
1.5
1.5
mmol/l
0.15
271
3001
126
980
1.43
2.63
2.2
1.8
100.4
98.8
pmol/l
0.14
64
513
93
685
1.47
2.58
2.5
2.0
3.2
2.9
mg/l
0.63
87
596
7
16
4.44
2.48
1.1
1.3
—
—
—
0
0
24
124
2.00
2.46
2.8
1.6
0.2
0.2
g/l
0.43
24
119
42
261
1.68
2.42
2.1
1.7
—
—
—
0
0
300
3224
0.68
2.40
4.1
4.0
2.9
2.9
mmol/l
0.04
278
3038
52
343
1.60
2.38
6.7
2.5
4.6
6.9
umol/l
1.09
43
297
296
3188
0.69
2.38
3.9
3.7
4.8
4.8
mmol/l
0.06
277
3028
40
249
1.68
2.30
2.9
4.3
218.7
234.2
u/l
0.61
40
242
24
128
1.93
2.27
5.9
2.5
0.0
0.1
e6/l
1.38
24
123
22
114
1.99
2.25
1.5
1.6
—
—
—
0
0
24
131
1.89
2.13
2.9
1.6
1.1
1.2
g/l
1.20
24
124
5
10
5.05
2.07
1.0
1.0
87.6
95.8
%
—
5
10
5
10
5.05
2.07
1.0
1.0
—
—
—
0
0
13
56
2.37
2.07
1.1
1.2
—
—
—
0
0
284
3061
0.72
2.03
3.6
3.3
1.2
1.2
mmol/l
0.01
263
2881
9
32
2.85
2.01
1.6
1.1
—
—
—
0
0
9
32
2.85
2.01
1.6
1.1
—
—
—
0
0
9
33
2.77
1.94
1.6
1.1
—
—
—
0
0
9
33
2.77
1.94
1.6
1.1
—
—
—
0
0
9
33
2.77
1.94
1.6
1.1
—
—
—
0
0
6
17
3.57
1.84
1.0
4.0
802.3
604.6
u/ml
—
6
17
112
904
1.34
1.78
2.9
3.1
2.4
2.3
mmol/l
0.08
101
816
9
36
2.54
1.75
1.3
1.4
—
—
—
0
0
184
1595
1.30
1.74
3.1
2.8
106.5
78.8
ug/l
1.09
175
1500
6
148
0.40
1.67
1.5
1.5
—
—
—
0
0
29
182
1.64
1.66
2.2
1.5
—
—
—
0
0
19
106
1.83
1.62
1.7
2.0
—
—
—
0
0
112
918
1.31
1.59
2.7
2.3
53.3
55.7
u/l
0.39
106
861
6
20
3.03
1.58
4.2
1.4
—
—
—
0
0
27
410
0.63
1.50
1.9
1.6
—
—
—
0
0
34
228
1.54
1.50
3.1
3.5
4.5
4.6
pmol/l
0.41
27
203
54
404
1.39
1.39
2.7
1.8
—
—
—
0
0
10
47
2.16
1.35
2.8
3.9
—
5348.0
—
0
5
45
329
1.42
1.32
3.3
2.2
20.8
24.3
%
0.85
35
282
11
55
2.03
1.28
2.5
4.1
—
1.2
—
0
6
317
3004
1.32
1.25
5.6
4.8
1.7
1.8
mu/l
0.63
303
2828
13
71
1.86
1.21
2.6
1.5
—
—
—
0
0
13
71
1.86
1.21
1.0
1.3
—
1.2
—
0
6
8
39
2.07
1.16
1.8
1.5
—
—
—
0
0
21
316
0.65
1.15
1.3
1.5
—
—
—
0
0
7
30
2.36
1.13
1.3
1.5
—
—
—
0
0
33
236
1.44
1.11
3.5
2.3
0.2
0.2
g/l
0.19
33
224
7
31
2.28
1.11
2.1
1.9
—
—
—
0
0
15
90
1.69
1.05
2.0
2.3
1.4
1.3
g/l
0.07
15
81
274
2571
1.23
1.05
4.5
4.2
14.5
14.4
pmol/l
0.54
254
2424
11
189
0.57
1.04
1.2
1.4
—
—
—
0
0
11
189
0.57
1.04
1.2
1.4
—
—
—
0
0
11
189
0.57
1.04
1.2
1.4
—
—
—
0
0
11
189
0.57
1.04
1.2
1.4
—
—
—
0
0
11
61
1.83
0.99
2.0
2.1
—
—
—
0
0
41
312
1.35
0.98
2.8
1.7
—
—
—
0
0
17
108
1.60
0.98
1.2
1.3
—
—
—
0
0
0
30
0.00
0.97
0.0
1.5
—
—
—
0
0
10
173
0.57
0.97
2.7
2.0
—
—
—
0
0
9
50
1.82
0.97
4.4
2.9
25.7
24.1
mmol/l
—
9
45
85
717
1.24
0.94
2.5
2.5
302.8
7657.7
umol/l
3.61
78
643
9
52
1.75
0.93
1.3
1.3
—
—
—
0
0
9
52
1.75
0.93
1.3
1.3
—
—
—
0
0
5
104
0.47
0.90
1.2
1.5
—
—
—
0
0
35
264
1.36
0.90
4.0
2.1
32.5
32.6
u/l
0.01
28
231
26
186
1.43
0.90
11.2
3.2
2.2
1.9
mmol/l
0.23
18
148
313
3003
1.23
0.83
15.4
9.5
93.8
90.2
ml/min/173m2
2.30
268
2444
46
368
1.28
0.80
3.3
3.9
20.4
22.4
%
0.28
19
137
0
25
0.00
0.79
0.0
2.6
—
—
—
0
0
7
125
0.55
0.79
1.3
1.7
—
—
—
0
0
31
237
1.34
0.75
6.7
7.2
1.3
1.2
mmol/l
0.02
21
184
83
717
1.20
0.74
1.8
1.8
0.6
0.8
mg/l
1.49
58
540
5
25
2.01
0.73
1.6
2.0
—
—
—
0
0
5
25
2.01
0.73
1.0
1.1
—
—
—
0
0
7
39
1.81
0.73
1.1
1.2
—
—
—
0
0
64
541
1.22
0.71
2.7
3.1
909.7
676.6
ng/l
0.18
57
444
10
61
1.66
0.69
2.6
1.2
—
—
—
0
0
11
71
1.57
0.62
1.2
1.3
—
—
—
0
0
5
30
1.68
0.61
1.6
1.1
—
1.1
—
0
12
23
174
1.34
0.61
6.7
3.3
89.2
71.0
ng/l
0.37
23
160
0
20
0.00
0.60
0.0
1.6
—
—
—
0
0
76
666
1.18
0.59
1.3
1.3
13.9
29.0
iu/ml
2.50
19
215
0
23
0.00
0.58
0.0
1.5
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
69
787
0.85
0.57
1.5
1.6
1.4
1.4
mmol/l
0.03
59
692
14
100
1.42
0.52
2.1
2.2
102.6
96.5
%
0.69
14
94
17
127
1.35
0.50
2.2
1.8
—
—
—
0
0
15
200
0.74
0.49
1.6
1.5
291.9
310.0
mu/l
0.12
15
179
13
177
0.73
0.48
1.9
2.1
4.7
2.3
mg/l
—
8
120
154
1446
1.11
0.43
4.5
3.8
—
—
—
0
0
15
195
0.76
0.42
1.3
1.5
—
—
—
0
0
5
32
1.57
0.42
1.0
1.1
—
—
—
0
0
8
58
1.39
0.41
1.6
1.8
—
—
—
0
0
5
33
1.52
0.41
1.4
1.2
—
—
—
0
0
7
101
0.69
0.40
1.0
1.4
—
—
—
0
0
76
689
1.13
0.39
2.7
2.0
—
—
—
0
0
9
66
1.37
0.38
1.0
1.1
—
—
—
0
0
6
43
1.40
0.35
1.3
1.3
—
—
—
0
0
89
823
1.11
0.33
1.3
1.2
0.7
1.9
u/ml
1.57
19
245
6
89
0.67
0.33
1.3
1.1
—
1.8
—
0
29
73
668
1.11
0.33
1.9
2.1
—
—
—
0
0
7
53
1.33
0.31
1.0
1.5
—
—
—
0
0
71
653
1.11
0.30
1.4
1.3
4.3
10.8
u/ml
1.00
26
276
29
251
1.17
0.29
3.3
3.0
—
—
—
0
0
7
57
1.23
0.29
1.0
1.5
—
—
—
0
0
8
63
1.28
0.28
1.6
1.4
—
—
—
0
0
8
66
1.22
0.27
1.1
1.1
—
—
—
0
0
26
225
1.17
0.26
1.9
2.1
34.1
42.7
u/ml
0.16
26
213
34
301
1.14
0.26
1.4
1.2
210.6
178.3
iu/ml
0.10
14
130
32
285
1.13
0.23
2.4
2.7
0.7
0.7
ug/l
0.01
21
157
5
40
1.25
0.22
1.0
1.5
—
—
—
0
0
5
41
1.22
0.22
1.0
1.5
—
—
—
0
0
23
201
1.15
0.21
6.9
6.1
1.4
1.2
mmol/l
0.36
23
192
5
42
1.19
0.21
1.0
1.5
—
—
—
0
0
5
42
1.19
0.21
1.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
4.3
—
—
—
0
0
0
12
0.00
0.21
0.0
4.3
—
—
—
0
0
5
43
1.16
0.21
1.0
1.4
—
—
—
0
0
5
43
1.16
0.21
1.0
1.4
—
—
—
0
0
5
43
1.16
0.21
1.0
1.4
—
—
—
0
0
5
43
1.16
0.21
1.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
112.8
—
0
13
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
25
221
1.14
0.20
2.2
2.3
73.7
78.9
ml/min/173m2
—
7
91
272
2768
0.94
0.19
5.1
4.5
38.3
38.4
mmol/mol
0.09
261
2637
22
194
1.14
0.19
1.5
1.5
—
—
—
0
0
33
300
1.11
0.18
9.1
5.7
—
—
—
0
0
7
61
1.15
0.17
1.9
1.9
—
—
—
0
0
19
214
0.88
0.16
1.0
1.0
—
—
—
0
0
20
178
1.13
0.15
1.3
1.6
—
—
—
0
0
9
78
1.16
0.15
1.9
1.5
—
—
—
0
0
318
3146
1.06
0.14
21.9
11.4
40.0
40.4
%
0.43
245
2578
89
855
1.05
0.14
1.7
1.6
—
—
—
0
0
20
221
0.90
0.13
1.2
1.5
—
—
—
0
0
64
613
1.05
0.11
1.8
1.9
—
—
—
0
0
15
134
1.12
0.11
5.2
5.0
24.3
24.6
mmol/l
0.21
15
134
85
823
1.04
0.10
1.6
1.5
—
—
—
0
0
17
155
1.10
0.09
1.6
1.4
—
—
—
0
0
13
117
1.12
0.08
1.0
1.1
—
5.5
—
0
21
7
64
1.10
0.08
1.4
1.2
—
—
—
0
0
7
82
0.85
0.07
1.0
1.2
—
—
—
0
0
9
104
0.86
0.06
1.6
1.2
—
—
—
0
0
9
104
0.86
0.06
1.6
1.2
—
—
—
0
0
26
250
1.04
0.03
18.5
17.0
1.3
1.2
inr
—
7
35
303
3018
1.02
0.03
4.0
3.6
5.8
5.7
mmol/l
0.28
284
2821
23
222
1.04
0.02
1.7
1.4
—
—
—
0
0
262
2630
0.99
0.02
3.4
3.7
—
—
—
0
0
9
95
0.95
0.00
1.3
1.5
20.0
22.9
u/l
—
9
77
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
8
81
0.99
0.00
1.4
1.5
—
—
—
0
0
7
70
1.00
0.00
1.1
1.4
—
—
—
0
0
5
51
0.98
0.00
1.2
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
4.0
—
101.1
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint G6_DISSOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DISSOTH | 2.024 [1.58, 2.6] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.361 |
During the follow-up period (1.1.1998 — 31.12.2019), 114 out of 1346 females with G6_DISSOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DISSOTH | 2.036 [1.57, 2.63] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.018 |
During the follow-up period (1.1.1998 — 31.12.2019), 94 out of 622 males with G6_DISSOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_DISSOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.179% | 0.402% |
| 5 | 1.097% | 2.427% |
| 10 | 3.192% | 6.325% |
| 15 | 6.203% | 11.838% |
| 20 | 10.507% | 19.86% |
Relationships between endpoints
↥Index endpoint: G6_DISSOTH – Other acute disseminated demyelination
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data